Taxynergy: Randomized Trial Of Early Switch From First-Line Docetaxel (D) To Cabazitaxel (C) Or Vice Versa With Circulating Tumor Cell (Ctc) Biomarkers In Patients (Pts) With Metastatic Castration-Resistant Prostate Cancer (Mcrpc).
JOURNAL OF CLINICAL ONCOLOGY（2016）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要